Monoclonal antibody cocktail to treat Marburg virus disease
Official title: Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease
Funded at Abvacc, INC. · NIH-11337576 · Data updated 2026-11-12
A new antibody-based treatment approach is being developed to help people infected with Marburg virus, using a combination of two targeted antibodies.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abvacc, INC. NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project start | August 11, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,000,000 |
| NIH project number | 5R44AI179371-03 |
| Project ID | NIH-11337576 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with suspected or confirmed Marburg virus exposure or infection could benefit from this therapy in future trials and eventual treatment settings.
✕Less likely to help
Not all patients will respond to antibody therapy, and access will depend on regulatory approval and trial availability.
What this research studies
This project aims to develop a pair of antibodies that bind to different parts of the Marburg virus glycoprotein to block infection. The approach builds on lessons from Ebola and SARS-CoV-2 antibody therapies and includes engineering to improve how long the antibodies stay in the body and how well they work. The work involves testing in preclinical models and moving toward manufacturing-ready candidates with a fast-track SBIR pathway. If successful, the therapy could become a much-needed option for people at risk during Marburg outbreaks.
Why it matters
Potential benefit: If successful, the treatment could provide a potent option to reduce illness and death from Marburg virus disease.
How similar studies have gone: Antibody cocktails have shown promise for Ebola and SARS-CoV-2, supporting the potential effectiveness of this approach for Marburg.
Where this research is happening
-
Abvacc, INC.
Rockville, United States Active
Researchers
- Principal investigator: Aman, M Javad — Abvacc, INC.
- Study coordinator: Aman, M Javad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.